Genentech has developed a monomeric degrader of PI3K, GDC-0077, that has recently entered clinical trials as a treatment for metastatic breast cancer. Here, I show that treatment of HCC1954 cells with GDC-0077 activates chaperone-mediated autophagy (CMA), a process by which proteins are recruited to the lysosome for degradation. This study aims to determine if the efficacy of GDC-0077 arises strictly from PI3K degradation, or the activation of CMA and degradation of other key survival proteins.